NO20054714L - Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom - Google Patents

Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom

Info

Publication number
NO20054714L
NO20054714L NO20054714A NO20054714A NO20054714L NO 20054714 L NO20054714 L NO 20054714L NO 20054714 A NO20054714 A NO 20054714A NO 20054714 A NO20054714 A NO 20054714A NO 20054714 L NO20054714 L NO 20054714L
Authority
NO
Norway
Prior art keywords
disease
procedures
preventing
cognitive impairments
alzheimer
Prior art date
Application number
NO20054714A
Other languages
English (en)
Other versions
NO20054714D0 (no
Inventor
Mark Steven Shearman
Mervyn Turner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20054714D0 publication Critical patent/NO20054714D0/no
Publication of NO20054714L publication Critical patent/NO20054714L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det er beskrevet anvendelse av en forbindelse av formel I eller et farmasøytisk akseptabelt salt derav, for fremstilling av et medikament for behandling av aldersrelatert kognitivt forfall eller mild kognitiv svekkelse, i særdeleshet for å forhindre eller forsinke starten av Alzheimers sykdom.
NO20054714A 2003-03-14 2005-10-13 Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom NO20054714L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45458903P 2003-03-14 2003-03-14
PCT/GB2004/000983 WO2004080459A1 (en) 2003-03-14 2004-03-08 Method for treating mild cognitive impairment and for preventing or delaying alzheimer’s disease

Publications (2)

Publication Number Publication Date
NO20054714D0 NO20054714D0 (no) 2005-10-13
NO20054714L true NO20054714L (no) 2005-11-16

Family

ID=32990914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054714A NO20054714L (no) 2003-03-14 2005-10-13 Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom

Country Status (13)

Country Link
US (1) US20060241133A1 (no)
EP (1) EP1605940A1 (no)
JP (1) JP2006520371A (no)
KR (1) KR20050109990A (no)
CN (1) CN1794992A (no)
AU (1) AU2004218871A1 (no)
BR (1) BRPI0408295A (no)
CA (1) CA2518886A1 (no)
IS (1) IS8004A (no)
MX (1) MXPA05009850A (no)
NO (1) NO20054714L (no)
RU (1) RU2005131845A (no)
WO (1) WO2004080459A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
JP5274258B2 (ja) 2005-11-21 2013-08-28 アムジエン・インコーポレーテツド β−セクレターゼ調節物質及び使用方法
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
WO2008147547A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
JP5440984B2 (ja) 2007-05-25 2014-03-12 アムジエン・インコーポレーテツド β−セクレターゼ修飾剤としての置換ヒドロキシエチルアミン化合物および使用方法
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
CA2736130C (en) * 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US8735384B2 (en) 2010-01-19 2014-05-27 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
AU2011227501B9 (en) 2010-03-15 2013-08-22 Amgen Inc. Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as Beta - secretase modulators and their medical use
WO2011115938A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
LU92126B1 (fr) * 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
EP0823904A4 (en) * 1995-04-19 1998-09-09 Merck & Co Inc Process for the preparation of spiroindolines
US6028196A (en) * 1995-10-27 2000-02-22 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
WO1997041879A1 (en) * 1996-05-07 1997-11-13 Merck & Co., Inc. Enhancement of sleep with a growth hormone secretagogue
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
CN1261158C (zh) * 1998-09-03 2006-06-28 诺兰兹公司 生长激素在制备用于诱导神经保护作用的药剂中的应用
US6849597B2 (en) * 1999-12-28 2005-02-01 Kaken Pharmaceutical Co., Ltd. Neuroprotective drug
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues

Also Published As

Publication number Publication date
KR20050109990A (ko) 2005-11-22
EP1605940A1 (en) 2005-12-21
US20060241133A1 (en) 2006-10-26
AU2004218871A1 (en) 2004-09-23
WO2004080459A1 (en) 2004-09-23
BRPI0408295A (pt) 2006-03-07
RU2005131845A (ru) 2006-02-10
CA2518886A1 (en) 2004-09-23
MXPA05009850A (es) 2005-12-06
CN1794992A (zh) 2006-06-28
IS8004A (is) 2005-08-29
NO20054714D0 (no) 2005-10-13
JP2006520371A (ja) 2006-09-07

Similar Documents

Publication Publication Date Title
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
GB0005251D0 (en) Therapeutic compounds
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
EA200400881A1 (ru) Азаарилпиперазины
SE0202462D0 (sv) Novel use
GB0318447D0 (en) Therapeutic agents
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
JO2282B1 (en) Oxazole derivatives
GB0225474D0 (en) Therapeutic agents
MXPA05010958A (es) Derivados indazol como inhibidores jnk.
EG25822A (en) Quinolinyl-pyrrolopyrazoles
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
WO2004029031A3 (en) Therapeutic piperazine compounds
SE0202429D0 (sv) Novel Compounds
EA200401114A3 (ru) Замещённые гидроксиэтиламины
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
NZ790364A (en) Compounds and compositions for use in treating skin disorders
GB0130677D0 (en) Medicaments and novel compounds
MY133527A (en) Isoquinoline derivatives
NO20034301L (no) Cyano-substituerte dihydropyrimidin forbindelser
BRPI0408295A (pt) uso de um composto
MY139368A (en) Novel cyclohexyl sulphones